<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00004105</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000067324</org_study_id>
    <secondary_id>P30CA016087</secondary_id>
    <secondary_id>NYU-9712</secondary_id>
    <secondary_id>NCI-G99-1596</secondary_id>
    <nct_id>NCT00004105</nct_id>
  </id_info>
  <brief_title>Combination Chemotherapy in Treating Patients With Advanced Cancer</brief_title>
  <official_title>A Phase I/II Study of Paclitaxel, Estramustine Phosphate, and Vinorelbine (PaclEVin)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>New York University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>New York University School of Medicine</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing
      so they stop growing or die. Combining more than one drug may kill more cancer cells.

      PURPOSE: Phase I/II trial to study the effectiveness of vinorelbine, paclitaxel, and
      estramustine in treating patients who have advanced cancer that has not responded to previous
      treatment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES: I. Establish the maximum tolerated doses (MTDs) and recommended Phase II doses
      (RPTDs) of vinorelbine and paclitaxel when combined with a fixed dose of estramustine in
      patients with advanced cancers or metastatic prostate cancer. II. Determine the toxicity
      pattern of this regimen at the MTDs and at the RPTDs in these patients. III. Make preliminary
      observations of antitumor activity in these patients treated with this regimen as leads for
      the Phase II portion of this study. IV. Establish the efficacy of the RPTDs of vinorelbine
      and paclitaxel when combined with estramustine in patients with prostate cancer who fulfill
      the criteria for the Phase II portion of this study.

      OUTLINE: This is a dose escalation, multicenter study of vinorelbine and paclitaxel. Patients
      receive oral estramustine every 8 hours on days 0-2 and 7-9 and vinorelbine IV over 6-10
      minutes immediately followed by paclitaxel IV over 1 hour on days 2 and 9. Courses repeat
      every 21 days. Patients with complete response, partial response, or stable disease continue
      treatment indefinitely in the absence of disease progression or unacceptable toxicity.
      Cohorts of 3-6 patients receive escalating doses of vinorelbine and paclitaxel until the
      maximum tolerated dose (MTD) of each drug is determined. The MTD is defined as the lowest
      dose at which 2 or more of 3-6 patients experience dose limiting toxicity. The recommended
      Phase II dose of vinorelbine or paclitaxel is defined as the dose immediately preceding the
      MTD.

      PROJECTED ACCRUAL: A minimum of 12-16 patients will be accrued over 1 year for Phase I of the
      study and a total of 14-25 patients will be accrued for Phase II of the study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 1998</start_date>
  <primary_completion_date type="Actual">April 2003</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <condition>Leukemia</condition>
  <condition>Lymphoma</condition>
  <condition>Sarcoma</condition>
  <condition>Unspecified Adult Solid Tumor, Protocol Specific</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>estramustine phosphate sodium</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>paclitaxel</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vinorelbine ditartrate</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS: Phase I: Histologically proven advanced cancer that has failed or
        is not amenable to standard treatment Phase II: Histologically proven metastatic prostate
        cancer as documented by bone scan and rising PSA Measurable or evaluable disease

        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: 0-2 Life expectancy: Not
        specified Hematopoietic: Neutrophil count at least 1,500/mm3 Platelet count at least
        100,000/mm3 Hemoglobin greater than 9 g/dL (transfusion allowed) Hepatic: AST and ALT no
        greater than 4 times upper limit of normal Bilirubin no greater than 2 mg/dL Renal:
        Creatinine no greater than 2 mg/dL Cardiovascular: No myocardial infarction within the past
        year No New York Heart Association class III or IV heart disease No uncontrolled cardiac
        dysrhythmia No angina pectoris No uncontrolled hypertension No cardiomyopathy Neurologic:
        No prior neuropathy No preexisting neurotoxicity Other: Not pregnant or nursing Negative
        pregnancy test Fertile patients must use effective contraception

        PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: Phase I: No prior
        vinorelbine (any schedule) or paclitaxel on a 24 hour or longer schedule At least 2 weeks
        since prior chemotherapy Phase II: No prior chemotherapy Endocrine therapy: Not specified
        Radiotherapy: No radiotherapy to greater than 25% of bone marrow At least 3 weeks since
        prior radiotherapy No concurrent radiotherapy during courses 1 and 2. Surgery: No
        concurrent oncologic surgery during courses 1 and 2
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Franco M. Muggia, MD</last_name>
    <role>Study Chair</role>
    <affiliation>New York University School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>NYU School of Medicine's Kaplan Comprehensive Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 10, 1999</study_first_submitted>
  <study_first_submitted_qc>May 24, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 25, 2004</study_first_posted>
  <last_update_submitted>March 25, 2011</last_update_submitted>
  <last_update_submitted_qc>March 25, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 28, 2011</last_update_posted>
  <keyword>stage III adult Hodgkin lymphoma</keyword>
  <keyword>stage IV adult Hodgkin lymphoma</keyword>
  <keyword>recurrent adult Hodgkin lymphoma</keyword>
  <keyword>stage III chronic lymphocytic leukemia</keyword>
  <keyword>stage IV chronic lymphocytic leukemia</keyword>
  <keyword>recurrent adult acute myeloid leukemia</keyword>
  <keyword>unspecified adult solid tumor, protocol specific</keyword>
  <keyword>childhood fibrosarcoma</keyword>
  <keyword>stage III grade 1 follicular lymphoma</keyword>
  <keyword>stage III grade 2 follicular lymphoma</keyword>
  <keyword>stage III grade 3 follicular lymphoma</keyword>
  <keyword>stage III adult diffuse small cleaved cell lymphoma</keyword>
  <keyword>stage III adult diffuse mixed cell lymphoma</keyword>
  <keyword>stage III adult diffuse large cell lymphoma</keyword>
  <keyword>stage III adult immunoblastic large cell lymphoma</keyword>
  <keyword>stage III adult lymphoblastic lymphoma</keyword>
  <keyword>stage III adult Burkitt lymphoma</keyword>
  <keyword>stage IV grade 1 follicular lymphoma</keyword>
  <keyword>stage IV grade 2 follicular lymphoma</keyword>
  <keyword>stage IV grade 3 follicular lymphoma</keyword>
  <keyword>stage IV adult diffuse small cleaved cell lymphoma</keyword>
  <keyword>stage IV adult diffuse mixed cell lymphoma</keyword>
  <keyword>stage IV adult diffuse large cell lymphoma</keyword>
  <keyword>stage IV adult immunoblastic large cell lymphoma</keyword>
  <keyword>stage IV adult lymphoblastic lymphoma</keyword>
  <keyword>stage IV adult Burkitt lymphoma</keyword>
  <keyword>recurrent grade 1 follicular lymphoma</keyword>
  <keyword>recurrent grade 2 follicular lymphoma</keyword>
  <keyword>recurrent grade 3 follicular lymphoma</keyword>
  <keyword>recurrent adult diffuse small cleaved cell lymphoma</keyword>
  <keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
  <keyword>recurrent adult diffuse large cell lymphoma</keyword>
  <keyword>recurrent adult immunoblastic large cell lymphoma</keyword>
  <keyword>recurrent adult lymphoblastic lymphoma</keyword>
  <keyword>recurrent adult Burkitt lymphoma</keyword>
  <keyword>stage III adult T-cell leukemia/lymphoma</keyword>
  <keyword>stage IV adult T-cell leukemia/lymphoma</keyword>
  <keyword>recurrent adult T-cell leukemia/lymphoma</keyword>
  <keyword>stage III mantle cell lymphoma</keyword>
  <keyword>stage IV mantle cell lymphoma</keyword>
  <keyword>recurrent mantle cell lymphoma</keyword>
  <keyword>recurrent marginal zone lymphoma</keyword>
  <keyword>recurrent small lymphocytic lymphoma</keyword>
  <keyword>stage III small lymphocytic lymphoma</keyword>
  <keyword>stage III marginal zone lymphoma</keyword>
  <keyword>stage IV small lymphocytic lymphoma</keyword>
  <keyword>stage IV marginal zone lymphoma</keyword>
  <keyword>extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue</keyword>
  <keyword>nodal marginal zone B-cell lymphoma</keyword>
  <keyword>splenic marginal zone lymphoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Leukemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Vinorelbine</mesh_term>
    <mesh_term>Vinblastine</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
    <mesh_term>Estramustine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

